RE:RE:RE:RE:RE:Great Plenty of time to formulate questions, so no need to rush on that Scarlett. Also, it is concievable that the date was picked because there will be nformation announced on new cancer reserach THTX has completed before then. If so, that might change the questions you want to submit so putting questions in too soon may be unproductive.
THTX is trying to rebrand the stock. It is a big job and they have a good group in LSA to ehlp them do that. My guess is that there will be some notable news release prior to the actual 6/21 event that will help bring people, other than loyal long term sharehodlers like ourselves, to it. Hopefully, that is the way it plays out.
We also still have the NASH phase II protocol news. I guess we are at the mercy fo the EMA in terms of when we get that news but it likely cannot be too far off now.
qwerty22 wrote: 18 days to go
scarlet1967 wrote: I did submit some questions, I find it odd that they didn't issue a PR or posting the news on their social media platforms!
Wino115 wrote: Keep it coming THTX/LSA. Information to aid in evaluating the company's pipeline is crucial. There's a button to send in questinos prior to the event. We should think about the most important issues for the whole SORT1+ and the Phase 1 trial and submit them. Better to get the best questions in so they are answered and not innundate them with too many.
Science minds, start thinking!
SPCEO1 wrote: Excellent news! TH continues to lead with cancer versus NASH which likely indicates things are following an encouraging path so far in the cancer phase I trial.
scarlet1967 wrote: In case you did not receive this already, please see below for information on an upcoming investor event highlighting our SORT1+ Technology, featuring key opinion leader Dr. Richard Beliveau, taking place on Monday, June 21, 2021 at 11:00am ET.
| The webinar will feature a presentation by Key Opinion Leader (KOL) Richard Bliveau, Ph.D. (Universit du Qubec Montral) who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Bliveau will be available to answer questions following the formal presentations. Theratechnologies' management team will also give an update on their oncology pipeline including TH1902, the Company's lead investigational peptide-drug conjugate (PDC) stemming from its SORT1+ Technology™ in oncology. SORT1+ Technology is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell. TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial. |